IMRX Stock Price, Immuneering Corporation Quote, Chart

Market Summary

USD1.56+0.03

Market Closed

1.96%

IMRX Alerts

2 major insider buys and 1 major insider sales recently.

IMRX Stock Price

View Fullscreen

IMRX RSI Chart

IMRX Valuation

Market Cap

44.3M

Price/Earnings (Trailing)

-0.83

Price/Sales (Trailing)

180.21

EV/EBITDA

0.05

Price/Free Cashflow

-0.9

IMRX Price/Sales (Trailing)

IMRX Profitability

Operating Margin

100.00%

EBT Margin

-15937.29%

Return on Equity

-59.03%

Return on Assets

-52.12%

Free Cashflow Yield

-111.24%

IMRX Fundamentals

IMRX Revenue

IMRX Earnings

Earnings (TTM)

-53.5M

Earnings Growth (Yr)

-13.88%

Earnings Growth (Qtr)

-19.76%

Breaking Down IMRX Revenue

Last 7 days

9.1%

Last 30 days

-37.6%

Last 90 days

-72.4%

Trailing 12 Months

-82.3%

How does IMRX drawdown profile look like?

IMRX Financial Health

Current Ratio

11.35

IMRX Investor Care

Shares Dilution (1Y)

7.69%

Diluted EPS (TTM)

-1.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.5M	949.8K	506.1K	317.0K
2021	2.3M	2.2M	2.1M	2.1M
2020	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Immuneering Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	cormorant asset management, lp	sold	-1,160,180	2.90045	-400,000	-
Mar 22, 2024	morales mallory	bought	1,000	2.5455	393	chief accounting officer
Mar 22, 2024	feinberg peter	bought	63,712	2.5485	25,000	-
Mar 22, 2024	schall thomas j.	bought	7,384	2.5465	2,900	-
Mar 22, 2024	brakewood harold eugene	bought	10,015	2.568	3,900	chief business officer
Mar 21, 2024	morales mallory	bought	3,008	2.7179	1,107	chief accounting officer
Mar 20, 2024	neufeld leah r	bought	10,993	2.8793	3,818	chief people officer
Mar 20, 2024	hall brett matthew	bought	20,020	2.86	7,000	chief scientific officer
Mar 19, 2024	zeskind benjamin j.	bought	55,326	2.7663	20,000	president and ceo
Mar 19, 2024	feinberg peter	bought	64,000	2.56	25,000	-

Which funds bought or sold IMRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	Janney Montgomery Scott LLC	reduced	-20.32	-102,000	46,000	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-81,717	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	11.00	11.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-16.01	-315,194	155,419	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-73.8	-17,000	2,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-3,715	82,739	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	464	155,946	283,954	0.01%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-6,600	147,000	-%

Are Funds Buying or Selling IMRX?

Are funds buying IMRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMRX

No. of Funds

IMRX Alerts

2 major insider buys and 1 major insider sales recently.

Unveiling Immuneering Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 15, 2024	cormorant asset management, lp	1.92%	561,128	SC 13G/A
Apr 10, 2024	price t rowe associates inc /md/	3.1%	910,266	SC 13G/A
Apr 05, 2024	blackrock inc.	4.7%	1,377,120	SC 13G/A
Mar 27, 2024	merrin investors llc	9.46%	2,770,386	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	11.5%	3,378,100	SC 13G/A
Feb 14, 2024	citadel advisors llc	7.0%	6	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	2,097,406	SC 13G
Jan 16, 2024	zeskind benjamin j.	12.6%	3,687,142	SC 13G/A
May 05, 2023	blackrock inc.	4.6%	1,336,436	SC 13G/A
Apr 24, 2023	cormorant asset management, lp	6.85%	1,996,779	SC 13G/A

Recent SEC filings of Immuneering Corporation

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 15, 2024	SC 13G/A	Major Ownership Report
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Mar 27, 2024	SC 13G/A	Major Ownership Report
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Immuneering Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Immuneering Corporation News

Latest updates

Immuneering Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-100.0%	-	455	38,380	94,419	183,698	189,591	482,130	660,040	748,200	715,385	682,570	480,835
Cost Of Revenue	-	-	-	19,343	47,933	90,846	206,221	219,088	318,601	409,163	-	315,002	237,062
Gross Profit	-100.0%	-	455	19,037	46,486	92,852	-16,630	263,042	341,439	339,037	-	367,568	243,773
Operating Expenses	16.6%	16,301,988	13,985,462	13,207,187	11,692,535	13,018,514	11,099,125	8,806,426	8,332,363	6,575,043	-	4,767,797	3,850,403
S&GA Expenses	6.7%	4,384,488	4,110,437	3,836,032	3,704,143	3,951,866	3,148,637	2,598,940	1,340,398	1,184,023	-	698,760	629,403
R&D Expenses	20.7%	11,910,183	9,867,710	9,363,838	7,981,075	9,058,545	7,950,488	6,207,486	6,991,965	5,391,020	-	4,069,037	3,221,000
EBITDA Margin	0.1%	-158	-158	-66.51	-35.49	-22.28	-16.25	-7.96	-7.75	-7.55	-7.36	-	-
EBT Margin	0%	-159	-159	-66.87	-35.63	-22.33	-16.27	-7.97	-7.76	-7.56	-7.37	-	-
Net Income	-13.9%	-15,083,492	-13,245,561	-12,844,330	-11,527,303	-12,896,374	-10,784,359	-8,534,073	-7,987,665	-6,229,651	-5,835,937	-4,399,079	-3,604,162
Net Income Margin	-5.9%	-168	-159	-94.95	-46.05	-26.53	-16.12	-13.37	-11.14	-8.91	-7.37	-	-
Free Cashflow	-1.1%	-11,946,119	-11,817,916	-11,015,473	-9,614,270	-12,396,089	-9,252,042	-9,045,975	-6,457,247	-6,156,404	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-9.9%	103	114	125	108	122	134	142	152	167	164	53.00	38.00
Current Assets	-11.4%	89.00	101	112	94.00	109	120	129	140	152	153	51.00	38.00
Cash Equivalents	-12.7%	59.00	68.00	104	77.00	73.00	76.00	88.00	75.00	75.00	107	50.00	37.00
Net PPE	0.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Goodwill	0%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	-	-	-
Liabilities	21.7%	12.00	10.00	10.00	10.00	13.00	12.00	8.00	8.00	11.00	6.00	5.00	3.00
Current Liabilities	39.5%	8.00	6.00	5.00	6.00	8.00	7.00	4.00	4.00	6.00	5.00	5.00	2.00
Shareholder's Equity	-12.9%	91.00	104	115	98.00	110	122	134	144	156	158	-	-
Retained Earnings	-10.2%	-163	-148	-135	-123	-109	-96.54	-83.70	-72.17	-59.27	-48.49	-39.95	-25.74
Additional Paid-In Capital	0.7%	254	252	251	221	220	219	217	216	215	207	5.00	3.00
Shares Outstanding	1.0%	28.00	28.00	28.00	26.00	26.00	26.00	26.00	26.00	14.00	18.00	5.00	5.00
Float	-	-	-	239	-	-	-	112	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	2.1%	-11,775	-12,026	-10,748	-14,418	-11,748	-10,622	-9,449	-12,281	-9,238	-9,034	-6,437	-6,139	-	-	-
Share Based Compensation	10.9%	1,641	1,479	1,334	1,274	1,048	1,066	1,052	898	633	637	351	182	-	-	-
Cashflow From Investing	113.1%	3,133	-23,971	9,163	18,972	8,152	-880	22,154	12,405	-22,807	-52,771	-19.82	-16.56	-	-	-
Cashflow From Financing	-63.5%	8.00	21.00	28,172	239	-184	-17.21	28.00	193	8.00	118,489	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IMRX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Revenue	$ 0	$ 316,952
Cost of revenue	0	158,122
Gross profit	0	158,830
Operating expenses
Research and development	41,624,018	36,267,116
General and administrative	16,759,602	15,606,529
Amortization of intangible asset	29,267	30,053
Total operating expenses	58,412,887	51,903,698
Loss from operations	(58,412,887)	(51,744,868)
Other income (expense)
Interest income	3,606,996	1,014,456
Other income, net	1,334,269	216,844
Net loss	$ (53,471,622)	$ (50,513,568)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.88)	$ (1.91)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.88)	$ (1.91)
Weighted-average common shares outstanding, basic (in shares)	28,416,558	26,386,864
Weighted-average common shares outstanding, diluted (in shares)	28,416,558	26,386,864
Other comprehensive loss:
Unrealized gain from marketable securities	$ 29,342	$ 18,889
Comprehensive Loss	$ (53,442,280)	$ (50,494,679)

IMRX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 59,405,817	$ 72,636,886
Marketable securities, current	26,259,868	32,887,970
Accounts receivable	0	12,417
Prepaids and other current assets	3,417,984	3,209,536
Total current assets	89,083,669	108,746,809
Property and equipment, net	1,400,582	1,369,608
Goodwill	6,690,431	6,690,431
Intangible asset, net	379,680	408,947
Right-of-use assets, net	3,995,730	4,407,785
Other assets	1,034,446	743,703
Total assets	102,584,538	122,367,283
Current liabilities:
Accounts payable	2,111,666	3,154,557
Accrued expenses	5,173,960	4,500,993
Other liabilities	259,770	19,796
Lease liabilities	300,107	378,723
Total current liabilities	7,845,503	8,054,069
Long-term liabilities:
Lease liabilities, net of current portion	4,162,852	4,462,959
Total liabilities	12,008,355	12,517,028
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; 0 shares issued or outstanding at December 31, 2023 and December 31, 2022	0	0
Additional paid-in capital	253,806,267	219,640,912
Accumulated other comprehensive loss	(778)	(30,120)
Accumulated deficit	(163,258,578)	(109,786,956)
Total stockholders' equity	90,576,183	109,850,255
Total liabilities and stockholders' equity	102,584,538	122,367,283
Class A Common Stock
Stockholders’ equity:
Common stock	29,272	26,419
Class B Common Stock
Stockholders’ equity:
Common stock	$ 0	$ 0

About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

CEO	Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
WEBSITE	https://immuneering.com
INDUSTRY	Biotechnology
EMPLOYEES	66

Immuneering Corporation Frequently Asked Questions

What is the ticker symbol for Immuneering Corporation? What does IMRX stand for in stocks?

IMRX is the stock ticker symbol of Immuneering Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immuneering Corporation (IMRX)?

As of Thu May 02 2024, market cap of Immuneering Corporation is 44.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMRX stock?

You can check IMRX's fair value in chart for subscribers.

What is the fair value of IMRX stock?

You can check IMRX's fair value in chart for subscribers. The fair value of Immuneering Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immuneering Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immuneering Corporation a good stock to buy?

The fair value guage provides a quick view whether IMRX is over valued or under valued. Whether Immuneering Corporation is cheap or expensive depends on the assumptions which impact Immuneering Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMRX.

What is Immuneering Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, IMRX's PE ratio (Price to Earnings) is -0.83 and Price to Sales (PS) ratio is 180.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMRX PE ratio will change depending on the future growth rate expectations of investors.